济南阴茎背敏感神经阻断手术(济南严重前列腺炎治疗) (今日更新中)

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

KUWAIT CITY, Nov. 27 (Xinhua) -- Two warships from China on Sunday docked at Kuwait's Shuwaikh port to start a five-day official visit to the Gulf Arab emirate.The tour by the destroyer "Wuhan" and the frigate "Yulin" marked the first visit by Chinese naval vessels to Kuwait since the two countries established diplomatic ties 40 years ago."This visit marks a historic occasion and Kuwaiti navy looks forward to future cooperation to improve the relationship and friendship between our two navies," said Colonel Khaled Ahmad Abdallah from Kuwait's navy.The flotilla was part of the ninth Chinese naval convoy to conclude its escort mission in the Gulf of Aden and waters off Somalia.Commander of the flotilla Guan Jianguo hopes the visit would enhance mutual cooperation between the two navies, which in turn would contribute to boosting bilateral relations.The flotilla would visit Oman after its stay in Kuwait.

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.

YAGNON, Oct. 23 (Xinhua) -- Myanmar has launched anti-dengue high fever campaign in seven townships in Yangon simultaneously as a prevention measure against the disease, according to the Health Department Sunday.The campaign was carried out in the weekend in collaboration with health department staff and members of social organizations.Dengue preventive and control measures were occasionally launched in schools and wards in Myanmar with the aid of World Health Organization, U.N. Children Fund, three Disease Fund, Global Fund and Japan International Cooperation Agency.According to statistics, a total of 181 people died of dengue fever in Myanmar's Yangon region in the past five years alone, out of 19,000 such cases occurring in the region during the half decade.According to earlier report, the number of people infected with dengue fever in the whole country in 2009 amounted to 3,129 with 37 deaths registered.However, according to the Yangon City Development Committee, the city saw less dengue fever occurrence in 2010 with death rate reducing to one percent in the year from over six percent in 1970.Meanwhile, the Myanmar health authorities are stepping up preventive measures against dengue fever in this sensitive rainy season by extending injection to people.The authorities are also introducing medicine with better effect, combating larva, giving education talks on the prevention and control especially in markets.Dengue fever mostly infected under-15 children, especially those between three and nine years old, but now such disease had also been found among some adult people, the authorities said, warning that dengue fever occurs regardless of age and season.Myanmar, along with Indonesia and Thailand, suffers dengue outbreak most in Southeast Asia region that makes up 52 percent of the dengue-prone areas in the world.

QINGDAO, Shandong, Dec. 26 (Xinhua) -- China's largest rail vehicle maker, CSR Corp. Ltd, over the weekend launched its first test train that features speeds reaching up to 500 km per hour.The six-car train with a fairshaped head is the newest in the CRH series. It has a maximum tractive power of 22,800 kilowatts, compared with 9,600 kilowatts for the CRH380 trains currently in service on the Beijing-Shanghai High-Speed Railway, which hold the world speed record of 300 km per hour.The grey-color train carrying testing and data processing facilities was designed and produced by CSR Sifang Locomotive & Rolling Stock Co., Ltd (Sifang Locomotive), a CSR subsidiary based in the coastal city of Qingdao in eastern Shandong province.Ding Sansan, the company's chief technician, said the concept of the the super-speed train design was inspired by China's ancient sword. The bodywork uses plastic materials reinforced with carbon fiber.Shen Zhiyun, a locomotive expert and academician with both the Chinese academies of sciences and engineering, said the testing of the super-speed train with speeds of up to 500 km per hour will provide useful reference for current high-speed railway operations.

来源：资阳报